Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669599 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 592
- Enrollment target
NCT05669599: Completed Phase 2 study, sponsored by Amgen.
NCT05669599 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 592 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (345% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669599, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 592 participants
- Enrollment target
Study Summary
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).
Interventions
- DRUG Placebo
- BIOLOGICAL Maridebart Cafraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 2 |
What the finished NCT05669599 record still lists
NCT05669599 is an interventional study that assigns participants to a tested intervention. The registered 592 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (345% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05669599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05669599 about?
NCT05669599 is a clinical study titled "Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus". The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overw...
What is the current status of trial NCT05669599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 592 participants. The study started on 2023-01-18. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT05669599?
The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT05669599?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05669599's enrollment target sits among peer trials
592 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI